Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes
27 August 2021
ESC Premium Access
SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis
27 August 2021
ESC Premium Access
Benefits of SGLT2-1/2 Inhibition on Heart Failure, Ischemic, and Kidney Endpoints